Under construction – not a live service
Sign in
SuspendedNo phase

Cancer Risk Assessment in Patients With a Constitutional Alteration of the PTEN Gene

Reason given: Cyber attack of the enrollment system, new system on going to be implemented

Key facts

Where
Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Chambéry, Colmar, Dijon, Grenoble, Le Mans, Lille, Limoges, Lyon, Marseille, Montpellier, Nantes, Nice, Nîmes, Niort, Paris, Pointe à Pitre, Poitiers, Reims, Rennes, Rouen, Saint-Etienne, Strasbourg, Toulouse, Tours, Troyes, Valence, and Villejuif, FranceSee the 45 sites

Where in France

  • 1-CHU AmiensAmiens, FranceNo longer taking part
  • 2-CHU AngersAngers, FranceNo longer taking part
  • 3-ICO Angers et NantesAngers, FranceNo longer taking part
  • 4-CHU BesançonBesançon, FranceNo longer taking part
  • 5-CHU BordeauxBordeaux, FranceNo longer taking part
  • 6-Institut BergoniéBordeaux, FranceNo longer taking part
  • 7-CHU BrestBrest, FranceNo longer taking part
  • 8-Centre François BaclesseCaen, FranceNo longer taking part
  • 9-CH Métropole Savoie ChambéryChambéry, FranceNo longer taking part
  • 10-CHU ColmarColmar, FranceNo longer taking part
  • 11-CHU DijonDijon, FranceNo longer taking part
  • 12-CHU GrenobleGrenoble, FranceNo longer taking part
  • 36-CH Le MansLe Mans, FranceNo longer taking part
  • 16-CHU LilleLille, FranceNo longer taking part
  • 17-CHU LimogesLimoges, FranceNo longer taking part
  • 18a-Hospices Civils Lyon - Lyon EstLyon, FranceNo longer taking part
  • 18b-Hospices Civils Lyon - Lyon SudLyon, FranceNo longer taking part
  • 19-AP-HM Hôpital de la TimoneMarseille, FranceNo longer taking part
  • 33-Institut Paoli CalmettesMarseille, FranceNo longer taking part
  • 20-CHU MontpellierMontpellier, FranceNo longer taking part
  • 21-CHU NantesNantes, FranceNo longer taking part
  • 22-CHU NiceNice, FranceNo longer taking part
  • 32-Centre Antoine LacassagneNice, FranceNo longer taking part
  • 23-CHU NîmesNîmes, FranceNo longer taking part
  • 37-CH NiortNiort, FranceNo longer taking part
  • 13a-AP-HP Hôpital AvicenneParis, FranceNo longer taking part
  • 13b-AP-HP Hôpital Saint-AntoineParis, FranceNo longer taking part
  • 13c-APH-HP Hôpital SalpétrièreParis, FranceNo longer taking part
  • 13d-AP-HP Hôpital TrousseauParis, FranceNo longer taking part
  • 13e-AP-HP Hôpital Saint-LouisParis, FranceNo longer taking part
  • 13f-AP-HP Hôpital Robert DebréParis, FranceNo longer taking part
  • 14-Institut CurieParis, FranceNo longer taking part
  • 38-CHU GuadeloupePointe à Pitre, FranceNo longer taking part
  • 24-CHU PoitiersPoitiers, FranceNo longer taking part
  • 25-Institut du Cancer CourlancyReims, FranceNo longer taking part
  • 26-Centre Eugène MarquisRennes, FranceNo longer taking part
  • 27-CHU RennesRennes, FranceNo longer taking part
  • 35-CHU RouenRouen, FranceNo longer taking part
  • 28-CHU Saint-EtienneSaint-Etienne, FranceNo longer taking part
  • 29-Institut StraussStrasbourg, FranceNo longer taking part
  • 30-CHU ToulouseToulouse, FranceNo longer taking part
  • 31-CHU ToursTours, FranceNo longer taking part
  • 40-CHU TroyesTroyes, FranceNo longer taking part
  • 34-CH ValenceValence, FranceNo longer taking part
  • 15-Institut Gustave RoussyVillejuif, FranceNo longer taking part

Trial details

Who runs it
Institut Bergonié
Trial code
NCT05630105
Record updated
15 May 2026
Original description
This is a multicentric, observational, retrospective and prospective study, aiming to estimate the risk of cancer occurrence in subjects carrying a PTEN mutation, based on the constitution of a national cohort.Read full original descriptionShow less

National Cohort of Patients With Cowden's Disease and With a Constitutional Alteration of the PTEN Gene for the Prospective Assessment of the Risk of Cancer.

This is a multicentric, observational, retrospective and prospective study, aiming to estimate the risk of cancer occurrence in subjects carrying a PTEN mutation, based on the constitution of a national cohort.

Inclusion: Male or female; Adult or child without age limit; Carrier of a constitutional or mosaic alteration of the PTEN gene established and/or confirmed by the Institut Bergonié's genetics laboratory, following a request for molecular diagnosis made between 1997 and 2027; Participant informed of his genetic diagnosis; Participant informed and not having expressed non-opposition to participate in the research; Participant affiliated to a French social security system in accordance with French law on research involving the human person.

Exclusion: Persons under psychiatric care, persons admitted to a health or social establishment for purposes other than research; Exception: a participant with autism may be included in the study; Participant under guardianship or curatorship. Exception: a participant with autism may be included in the study; Persons deprived of their liberty by a judicial or administrative decision.

ClinicalTrials.gov NCT05630105